American Journal of Cardiology
Volume 99, Issue 7 , Pages 890-895, 1 April 2007

Serum Complement C3/C4 Ratio, a Novel Marker for Recurrent Cardiovascular Events

  • Anil Palikhe, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
    • Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland
  • ,
  • Juha Sinisalo, MD, PhD

      Affiliations

    • Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Mikko Seppänen, MD

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Heikki Haario, PhD

      Affiliations

    • Laboratory of Applied Mathematics, Lappeenranta University of Technology, Lappeenranta, Finland.
  • ,
  • Seppo Meri, MD, PhD

      Affiliations

    • Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland
  • ,
  • Ville Valtonen, MD, PhD

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Markku S. Nieminen, MD, PhD

      Affiliations

    • Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • ,
  • Marja-Liisa Lokki, PhD

      Affiliations

    • Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland
    • Corresponding Author InformationCorresponding author: Tel: 358-9-191-26614; fax: 358-9-241-1227.

Received 29 August 2006; received in revised form 7 November 2006; accepted 7 November 2006.

Acute coronary syndrome is an inflammatory disease, during which the complement cascade is activated. We assessed the complement C3 and C4 concentration ratio (C3/C4 ratio) in serum as a potential measurement to predict cardiovascular attacks. Patients with acute coronary syndrome (n = 148) were followed after an initial attack for subsequent ischemic cardiovascular events (composite end point of death, myocardial infarction, recurrent unstable angina, or stroke). During the follow-up period (average 555 days), 44 patients met an end point. Blood samples were taken at hospitalization, 1 week, 3 months, and 1 year after hospital admission. Serum complement C3 and C4 concentrations and the C3/C4 ratio were analyzed. Patients with an end point had, throughout the follow-up period, a higher C3/C4 ratio than patients without these end points (repeated measures analysis of variance, p = 0.007). When all traditional cardiovascular risk factors and other potential confounding factors were included in a Cox multivariate logistic regression survival analysis, the C3/C4 ratio emerged as the novel risk factor for any new cardiovascular event (odds ratio 1.33, 95% confidence interval 1.08 to 1.63, p = 0.007). When the C3/C4 ratio was divided into 4 quartiles, 24% in quartiles 1 and 2 (lowest) and 48% in quartile 4 (highest) had end points during follow-up (odds ratio 3.04, 95% confidence interval 1.27 to 7.29, p = 0.01). In conclusion, increased serum C3/C4 ratio is a readily available and novel marker for recurrent cardiovascular events in acute coronary syndrome. The relative increase in serum C3 protein and decrease in C4 protein could explain changes in the C3/C4 ratio.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was funded by the University of Helsinki Foundation, Helsinki; the Finnish-Norwegian Medical Foundation, Helsinki; the Aarne Koskelo Foundation, Helsinki; the Finnish Foundation for Cardiovascular Research, Helsinki; the Helsinki University Central Hospital Research Funds (EVO), Helsinki; and the Finnish Red Cross Blood Transfusion Service Research Fund, Helsinki, Finland.

PII: S0002-9149(06)02486-6

doi:10.1016/j.amjcard.2006.11.034

American Journal of Cardiology
Volume 99, Issue 7 , Pages 890-895, 1 April 2007